tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Oruka Therapeutics reports Q2 EPS (46c), consensus (43c)
PremiumThe FlyOruka Therapeutics reports Q2 EPS (46c), consensus (43c)
28d ago
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
Premium
Ratings
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
2M ago
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation
Premium
Ratings
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation
2M ago
Oruka Therapeutics Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsOruka Therapeutics Holds Annual Stockholders Meeting
3M ago
Oruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
Oruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
3M ago
Oruka Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Oruka Therapeutics initiated with a Buy at BTIG
4M ago
Oruka Therapeutics Reports Strong 2024 Financial Results
PremiumCompany AnnouncementsOruka Therapeutics Reports Strong 2024 Financial Results
6M ago
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
Premium
Company Announcements
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
6M ago
Buy Rating for Oruka Therapeutics: Promising Drug Pipeline and Strategic Trial Design
Premium
Ratings
Buy Rating for Oruka Therapeutics: Promising Drug Pipeline and Strategic Trial Design
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100